共 11 条
[1]
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Slavin S,Nagler A,Naparstek E,et al. Blood . 1998
[2]
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Champlin R,Khouri I,Shimoni A,et al. British Journal of Haematology . 2000
[3]
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Wadhwa J,Szydlo RM,Apperley JF,et al. Blood . 2002
[4]
Imatinib alone and in combination for chronic myeloid leukemia. Druker BJ. Seminars in Hematology . 2003
[5]
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. A Gratwohl,J Hermans,JM Goldman. The Lancet . 1998
[6]
Completeremissionfromchronicmyelogenousleukemia———blasticcrisiscausedbyreducedintensitystemcelltransplantationfollowingpartialremissionduetoimatinib. MyojoT,HinoN. International Medical Journal . 2004
[7]
Secondchronicphasebeforetransplantationiscrucialforimprovingsurvivalofblasticphasechronicmyeloidleukaemia. VisaniG,RostiG,BandiniG, etal. British Journal of Haematology . 2000
[8]
Allogeneicbonemarrowtransplantationforchronicmyelogenousleukemia: comparativeanalysisofunrelatedversusmatchedsiblingdonortransplantation. WeisdorfDJ,AnasettiC,AntinJ, etal. Blood . 2002
[9]
Effcacy andsafety of aspecific inhibitor of the BCR-ABLtyrosine kinase in chronic myeloidleukemia. DRUKERBJ,TALPAZ M,RESTA DJ,et al. The New England Journal of Medicine . 2001